HC Wainwright & Co. Reiterates Buy on TRACON Pharma, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on TRACON Pharmaceuticals (NASDAQ:TCON) and maintained a price target of $7.
November 20, 2023 | 4:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reaffirmed a Buy rating on TRACON Pharmaceuticals with a price target of $7.
The reiteration of a Buy rating and the maintenance of a $7 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on TCON's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100